Lutetium-177-PSMA-617 (177Lu-PSMA-617), a type of targeted radiation therapy, is effective for men with advanced prostate cancer, even if they were previously treated with another radiation ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...

Some people with advanced castrate-resistant prostate cancer now have a new option: PSMA lutetium-177, also known as lutetium Lu 177 vipivotide tetraxetan, a radiopharmaceutical ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

The PSMA targeting ligand in Pluvicto™, is chemically attached to a therapeutic radioactive atom called Lutetium-177 (177Lu), which releases an energetic beta particle to precisely deliver cell ...

Phase 2 trial design will seek to maximise radiation doses to tumor and extend the duration of therapy, with first metastatic ...